Related Experiment Video

Updated: Mar 2, 2026

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

38.2K

Serotherapy for patients with severe influenza

Dorothy Scott1, Jay S Epstein1, Frederick G Hayden2

  • 1Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

The Lancet. Respiratory Medicine
|May 20, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Optimization of a Quantitative Micro-neutralization Assay
10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

22.0K
Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
12:09

Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells

Published on: November 22, 2017

19.0K

Related Experiment Videos

Last Updated: Mar 2, 2026

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

38.2K
Optimization of a Quantitative Micro-neutralization Assay
10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

22.0K
Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
12:09

Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells

Published on: November 22, 2017

19.0K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

903
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
903
Vaccinations01:51

Vaccinations

52.5K
Overview
52.5K

Articles linked to this work by shared authors, journal, and citation graph.

Antiviral Resistance in Influenza: Clinical and Public Health Implications.

Influenza and other respiratory viruses·2026

Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.

The New England journal of medicine·2026

Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection.

Proceedings of the National Academy of Sciences of the United States of America·2026

Introduction and Update: Advances in Influenza Therapeutics.

The Journal of infectious diseases·2025

Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance.

The Journal of infectious diseases·2025

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024

NEWS2 versus shock status to stratify antibiotic urgency in patients with suspected sepsis: a retrospective, multicentre cohort study.

The Lancet. Respiratory medicine·2026

Cryobiopsy versus conventional bronchoscopic sampling for peripheral pulmonary lesions (Cryo-RCT): an open-label, parallel-group, randomised trial.

The Lancet. Respiratory medicine·2026

Global economic burden attributable to asthma, 2025-50: a global modelling analysis of 154 countries and territories.

The Lancet. Respiratory medicine·2026

FEF25-75% trajectories from age 7 to 53 years, associations with childhood and parental preconception factors, and midlife COPD risk: a prospective cohort study.

The Lancet. Respiratory medicine·2026

The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis.

The Lancet. Respiratory medicine·2026

Reproductive health guidance for the cystic fibrosis community: a Cystic Fibrosis Foundation Position Paper.

The Lancet. Respiratory medicine·2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

JAMA neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us